Piper Jaffray analyst Edward Tenthoff recommends buying shares of Moderna on weakness ahead of the company's R&D day on September 12. Moderna has completed enrollment of the Phase I study of cytomegalovirus vaccine mRNA-1647 with data soon, and the company could also report preliminary Phase I data on intratumoral mRNA-2754 by the end of 2019, Tenthoff tells investors in a research note. Further, the analyst is focused on the Phase I chikungunya antibody mRNA-1944 data in Q4 for read-through to Moderna's orphan disease pipeline. He sees multiple clinical data readouts through the end of the year and reiterates an Overweight rating on the shares with a $30 price target.